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ABSTRACT
Introduction When health conditions are labelled it is 
often to classify and communicate a set of symptoms. 
While diagnostic labelling can provide explanation 
for an individual’s symptoms, it can also impact how 
individuals and others view those symptoms. Despite 
existing research regarding the effects of labelling health 
conditions, a synthesis of these effects has not occurred. 
We will conduct a systematic scoping review to synthesise 
the reported consequences and impact of being given a 
label for a health condition from an individual, societal and 
health practitioner perspective and explore in what context 
labelling of health conditions is considered important.
Methods and analysis The review will adhere to 
the Joanna Briggs Methodology for Scoping Reviews. 
Searches will be conducted in five electronic databases 
(PubMed, Embase, PsycINFO, Cochrane, CINAHL). 
Reference lists of included studies will be screened and 
forward and backward citation searching of included 
articles will be conducted. We will include reviews and 
original studies which describe the consequences for 
individuals labelled with a non- cancer health condition. 
We will exclude hypothetical research designs and 
studies focused on the consequences of labelling cancer 
conditions, intellectual disabilities and/or social attributes. 
We will conduct thematic analyses for qualitative data and 
descriptive or meta- analyses for quantitative data where 
appropriate.
Ethics and dissemination Ethical approval is not 
required for a scoping review. Results will be disseminated 
via publication in a peer- reviewed journal, conference 
presentations and lay- person summaries on various online 
platforms. Findings from this systematic scoping review 
will identify gaps in current understanding of how, when, 
why and for whom a diagnostic label is important and 
inform future research.
INTRODUCTION
The diagnosis of physical and psycholog-
ical health conditions is increasing in prev-
alence.1–5 Diagnoses often occur in the 
context of individuals seeking to identify 
and treat symptoms. However, diagnoses can 
also occur as a result of screening tests where 
individuals have no discernible signs or symp-
toms of disease (such as when a routine test 
determines an individual has hypertension),6 
from unanticipated findings in investigations 
for other health concerns (such as identi-
fying an anomaly in a person’s thyroid when 
conducting an MRI of the spine)7 or, when 
people are newly diagnosed with a health 
condition because of changes to diagnostic 
thresholds or cut- offs for the condition 
opposed to changes in individual circum-
stances (such as for gestational diabetes).1 
The value of a diagnosis, particularly in these 
latter contexts, is not always evident and the 
risk of overdiagnosis and misdiagnosis is 
significant.1 8 9
Diagnostic labels provide healthcare 
professionals with a framework from which 
to organise and interpret clinical symptom 
presentations, support clinical decision 
making through directing treatment deci-
sions, and provide information on possible 
condition course and overall prognosis.10 11 
Further, diagnostic labels allow clinicians to 
assume homogeneity among members of 
patient groups, in addition to providing an 
efficient method for health professionals to 
communicate.12
Despite well- meaning intentions, applica-
tion of diagnostic labels in real- world practice 
Strengths and limitations of this study
 ► A broad, comprehensive search strategy will be con-
ducted in five electronic databases.
 ► We will include both qualitative and quantitative 
studies which will enhance our current under-
standing of the consequences of health condition 
labelling.
 ► Two reviewers will screen 10% of titles and ab-
stracts, extract data and assess the quality of in-
cluded studies.
 ► Eligibility will not be limited to specific health con-
ditions, therefore, the consequences identified will 
be generalisable to health condition labelling more 
broadly.
 ► Articles will be limited to peer- reviewed publications 
and not include grey or theory- based literature.
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can be problematic. Diagnostic criteria can often be 
ambiguous. For example, symptoms of anxiety, such as 
restlessness, fatigue or difficulty concentrating, may be 
explained by diagnoses of anxiety, depressive, or bipolar 
and related disorders.13 14 Similarly, chest pain symptoms 
may be explained by several alternative diagnostic cate-
gories such as inflammatory diseases, musculoskeletal 
conditions or coronary diseases.15 16 Lastly, non- specific 
low back pain is the leading cause of disability worldwide, 
yet for the majority of people, no pathoanatomical cause 
can be identified.17
From the perspective of a patient, a diagnostic label 
can have a significant impact (negative and positive) 
on their health outcomes, psychological well- being and 
behaviour, and can influence how they are viewed and 
managed by healthcare professionals and are perceived 
by other members in society (eg, school, workplace).3 5 18 
In a cohort of over 33 000 adults, individuals who were 
aware that they had hypertension reported elevated levels 
of psychological distress compared with those individuals 
who had hypertension, however, were unaware of this.3 
A study investigating the impact of labelling borderline 
personality disorder on clinician interpretation of patient 
symptoms found clinicians’ prior awareness of a diagnosis 
of borderline personality disorder, compared to no aware-
ness, resulted in a tendency to frame observations of the 
individual in terms of the label, and a failure to observe 
positive behaviours.12
Conversely, a diagnostic label may have positive effects 
on the individual. These include timely referral to neces-
sary healthcare which, in turn, can reduce morbidity 
and mortality, improve predictions regarding condition 
progression as well as facilitate access to support, services 
and resources (eg, diagnosis- based school funding19 20 
and social support5), and provide an explanation and 
validation of an individual’s signs and symptoms. A recent 
study exploring the impact of chronic fatigue syndrome 
using hypothetical scenarios of a close friend’s diagnosis 
reported a label of chronic fatigue, compared with no 
label, elicited higher sympathetic responses from partic-
ipants, greater potential social support and greater 
support for active treatment.5
The terms used to describe a diagnostic label have been 
found to influence an individual’s behaviour, psycholog-
ical well- being and treatment preferences. Specifically, a 
diagnostic label that uses medicalised and precise termi-
nology compared with a description of symptoms has 
been found to result in higher patient anxiety, greater 
perceived severity of the condition and a patient prefer-
ence of more invasive treatments.18 21–23 This has been 
evidenced in conditions including gastro- oesophageal 
reflux disease, polycystic ovary syndrome, bone fracture 
and low back pain.18 21–23 Similarly, research suggests that 
patients diagnosed with diabetes demonstrate a propen-
sity to medical interventions, including insulin use, 
oral medication taking and blood glucose monitoring, 
compared to less invasive interventions, such as changes 
to diet and exercise practices.24 The use of a medicalised 
label over a descriptive label for a health condition is 
also suggested to result in increased confidence in the 
medical professional and greater adoption of sick role 
behaviour.25 Alternatively, use of descriptive labels for 
health conditions was found to be associated with greater 
patient ownership of the condition.25
To date, our understanding of the consequences 
and impacts of a diagnostic label has been limited to a 
single perspective (eg, patient, healthcare practitioner), 
single condition (eg, gastro- oesophageal reflux disease), 
or restricted to a specific study design (eg, hypothet-
ical research design) and a comprehensive synthesis of 
this information across health conditions is lacking.26 27 
Further, exploring the real- world impact of a diagnostic 
label including benefits and harms has received little 
attention.22 28 29 Therefore, the aims of this systematic 
scoping review are to systematically review original and 
synthesised research exploring the consequences of 
being given a label for a health condition to:
1. Identify the range of potential consequences of label-
ling of health conditions from an individual, societal 
and health practitioner viewpoint.
2. Explore why, for whom, and in what contexts labelling 
of health conditions is, or is not, influential.
3. Evaluate the methods used to study the impact of label-
ling health conditions.
METHODS AND ANALYSIS
Scoping reviews are suggested as an alternative to 
systematic reviews, allowing for a broader examination 
and synthesis of existing research and identification of 
research gaps.30 The proposed systematic scoping review 
will adhere to the Joanna Briggs Methodology for Scoping 
Reviews,31 and adhere to the Preferred Reporting Items 
for Systematic Reviews and Meta- Analyses Extension for 
Scoping Reviews (PRISMA- ScR).32 This approach was 
selected to allow sufficient documentation of the review 
process. An initial search was conducted in August 2019 
to pilot the screening process and data extraction spread-
sheet. The review is expected to be complete by October 
2020.
Consumer involvement in scoping review design and 
framework development
A convenience sampling survey was conducted to explore 
the publics opinion of the consequences of a diagnostic 
label for health conditions. In April 2019, we posted the 
questions ‘What are the labelling consequences of being 
given a health diagnosis? We’re working up a list and so 
far we have: anxiety, relief, more tests, stigma, medico- 
legal problems. What else?’ on two social media plat-
forms, Facebook and Twitter. Responses on Facebook 
included 14 comments from 6 individuals, while Twitter 
responses resulted in 45 comments from 40 individuals. 
The results of this survey were used to inform the devel-
opment of the search strategy, inclusion and exclusion 
criteria, data extraction form and an initial qualitative 
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framework (table 1) that will be used in this scoping 
review.
Inclusion criteria
Peer- reviewed publications including systematic or liter-
ature reviews and original studies which describe the 
perceived consequences for individuals labelled with a 
non- cancer health condition will be included. Perceived 
consequences can be reported from the perspectives of 
the individuals, their family, friends and/or carers or 
health professionals. As we expect individuals labelled as 
having a cancer condition will have different experiences 
to those labelled with general health conditions, studies 
that focus on these samples are excluded. Similarly, 
studies that report the consequence of labels for people 
using hypothetical case scenarios, or individuals with 
intellectual disabilities and/or social attributes such as 
race, sexual identity or orientation will also be excluded 
(see table 2 for more details).
Search strategy
A structured search, developed in collaboration with 
an information specialist, of five electronic databases 
(PubMed, Embase, PsycINFO, Cochrane, CINAHL) will 
be conducted to identify relevant publications. Data-
bases will be searched from their inception. Preliminary 
searches were conducted in August 2019 and will be 
updated in June 2020. Reference lists of included arti-
cles will be searched and forward citation searching of 
included articles will be conducted. The full search 
strategy to be used is reported in the online supplemental 
material.
Study selection
Titles and abstracts of 10% of articles retrieved through 
electronic and manual searches will be independently 
screened by two reviewers (RS and LK) for eligibility 
against the pre- specified inclusion criteria. Disagreements 
will be resolved through discussion and consultation 
with additional reviewers as required. When interrater 
reliability (κ) >0.8 is achieved for the screened studies, 
remaining studies will continue to be screened by one 
reviewer (RS). Articles identified as unclear for inclusion 
will be reviewed by an additional reviewer as required.
Data extraction and framework revision and validation
Full- text publications will be obtained and the reference 
list reviewed. Any relevant studies found in the reference 
list will be screened (RS) for inclusion against the same 
inclusion criteria. Additional uncertainties regarding 
eligibility for inclusion will be resolved through discussion 
with other reviewers (RT or PG). Two reviewers (RS and 
Table 1 Coding framework of social media responses
Name Description Examples
Psychological impact Psychological impact of diagnosis  ► Increased self- understanding
 ► Stigma (internalised stigma (self); perceived stigma from 
others)
 ► Increased psychological distress (anxiety, depression, 
phobia, worry, fear, stress)
Support Support gained or lost as a result of 
diagnosis
 ► Support groups: increased support of others with a 
similar diagnosis; network with other patients
 ► Others less respectful, more withdrawn and judgemental
Development
  Education Seeking to become more informed on 
diagnoses, testing, intervention
 ► Increase in health literacy due to motivation to find about 
treatment options
  Planning Forward planning and decision making 
as a result of diagnosis
 ► Ability to plan—even if there may not be treatment, 
provides an opportunity to get affairs in order (eg, wills)
Lifestyle
  Behaviour Behaviour changes as a result of 
diagnosis
 ► Change diet
 ► Change lifestyle
  Employment Effect of diagnosis on employment  ► More sick days; time off work; absenteeism
  Financial Effect of diagnosis on finances  ► Diagnosis provides access to funds (eg, Medicare, 
National Disability Insurance Scheme (NDIS), insurance)
Service use
  
  Testing
Further assessment and tests as a result 
of diagnosis (including testing of family)
 ► Seeking more investigations
 ► Scans and imaging
 ► Encourages screening of other family members at low- 
risk of the condition
  Treatment Treatment and intervention as a result of 
diagnosis
 ► Clear treatment path; clearer treatment protocols
 ► Side- effects (of medication: sexual, agitation, suicidality, 
emotional numbing)
copyright.
 on N
ovem
ber 2, 2020 at B
ond U
niversity. P
rotected by
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-037392 on 26 O
ctober 2020. D
ow
nloaded from
 
4 Sims R, et al. BMJ Open 2020;10:e037392. doi:10.1136/bmjopen-2020-037392
Open access 
ZAM) will independently extract study data from 10% of 
included qualitative studies and 10% of included quanti-
tative studies using a standardised data extraction form 
that will be piloted prior to use. Conflicts will be resolved 
by a third party as required. Once interrater reliability 
(κ) >0.8 is achieved for extracted data, one reviewer (RS) 
will undertake the remaining data extraction in a staged 
process, with this detailed below in the extraction sections. 
The same staged process will be used when extracting 
data from quantitative and qualitative studies. Queries 
will be resolved through discussion with a second reviewer 
(ZAM).
The methods used to extract and synthesise the results 
of qualitative and quantitative studies are based on the 
meta- analytic techniques described by Sandelowski et al,33 
Thomas and Harden34 and Timulak.35 Extracted data 
will include study characteristics (author, journal, year of 
publication, study country and setting), participant char-
acteristics (number of participants, age, health condition) 
and quantitative or qualitative outcomes (consequences, 
impact, effects of the diagnostic label).
Qualitative data extraction
Data for thematic analysis will be extracted from the 
published study and include the authors abstracted 
themes and relevant, supporting quotes, reported in 
the primary study. Direct quotes will not be extracted in 
isolation to ensure data ‘retains its meaning’ and is not 
interpreted or extracted out of the context of the primary 
study. This qualitative meta- analysis technique has been 
described by Sandelowski et al,33 Thomas and Harden34 
and Timulak.35
Quantitative data extraction
For studies with quantitative outcomes, extracted data 
will include, the text and numerical data from the results 
section reporting primary outcomes.36 Examples of 
potential quantitative measures include the Short Form 
Health Survey (SF-36),37 General Health Questionnaire 
(GHQ)38 or work absenteeism.
Qualitative data analysis
The coding framework developed from social media 
responses will be iteratively revised using eligible studies 
retrieved by the electronic database search. Qualitative 
data will initially be extracted from a random sample of 
one- third of included qualitative studies and mapped to 
the coding framework. This framework will be expanded 
as additional themes emerge. The second third of 
included qualitative studies will be randomly selected, 
data extracted and mapped to the updated coding frame-
work until data thematic saturation has been achieved. If 
new themes are still emerging at this point, the remaining 
third of qualitative studies will be analysed against the 
developed framework. Data saturation will be defined 
using indicative thematic saturation, which states data 
Table 2 Inclusion criteria
Aspect Inclusion criteria Exclusion criteria
Types of studies Original studies (cohort, case- controlled, cross- 
sectional, observational, Randomised Controlled Trial 
(RCT), focus groups)*
Synthesised studies (systematic reviews)
Protocols (final study to be sourced)
Opinion pieces and commentaries
Quantitative cohort, case- controlled and cross- 
sectional studies without comparator
Hypothetical or vignette- based studies
Participants Individuals, no age limit (eg, adults, children, family, 
carers, health professionals, general public)
Animal subjects
Condition Screening and/or labelling of physical or 
psychological health condition/s
Self- reported (eg, response to questions such as ‘has 
your GP ever told you that you have hypertension?’)
Health condition confirmed (eg, medical examination 
and testing completed as part of the study)
Labelling of intellectual impairment, race, ethnicity, 
sexual identity or sexual orientation
Labelling of cancers and cancer- related conditions
Self- reported conditions provided by unqualified 
professional (eg, physiotherapist telling patient they 
have hypertension)
Self- identified conditions (eg, googling of symptoms, 
no confirmation by a medical professional)
Outcomes Consequences, impact, effects of the health 
condition label or diagnosis
Perceived harms and/or benefits (eg, illness burden)
 ► Lived experience
 ► Psychological impact (eg, anxiety, quality of life)
 ► Behaviour change (eg, participation in 
employment)
 ► Support (eg, financial, social support)
Effect of the health condition (eg, disease 
mechanisms/traits)
Gene labelling
Food or nutrition labelling
Drug effects/effectiveness
Intervention effects/effectiveness
(eg, intervention A vs intervention B)
Language No language limitations –
Date No date limitations –
*Studies using qualitative methodologies do not require multiple group comparisons for inclusion.
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saturation as the non- emergence of new codes or themes 
that will result in expansion or revision of the coding 
framework.36
Quantitative data analysis
Quantitative data will be summarised narratively.33 For 
example, we will collate data from studies that used the 
SF-36, GHQ or absenteeism and summarise the findings 
reported in the results section. Unlike the large volume 
of expected qualitative studies, fewer quantitative studies 
with comparators are expected. Therefore, outcomes 
from all of the included quantitative studies will be 
extracted and, if possible, tabulated by condition and 
outcomes.
Patient and public involvement
This scoping review has no direct patient involvement.
PRESENTATION OF RESULTS
We will present study selection in a flow diagram 
according to PRISMA- ScR and included studies will be 
described in a table of characteristics.32 Results will be 
aggregated as appropriate. Results pertinent to the conse-
quences of labelling of health conditions will be collated 
to expand those provided in table 1, with empirical data 
regarding the rate and severity of these consequences 
also examined. Additionally, a compendium of methods 
used to elicit the consequences of health condition label-
ling will be developed and methodology appraised. For 
quantitative studies, extracted data will be tabulated in 
a descriptive and/or statistical manner depending on 
the availability of data (ie, number of studies reporting 
similar outcome measures or measurement of similar 
constructs, such as quality of life or symptoms of anxiety) 
and degree of heterogeneity between studies (eg, popula-
tion, clinical conditions). Should data not support a meta- 
analysis, results from studies which provide quantitative 
data will be reported in a narrative synthesis and inter-
preted alongside results from qualitative studies. Quali-
tative data will be analysed using developed frameworks 
(see table 1) and following established protocols for the 
qualitative analysis of information in the social sciences.39 
The characteristics and results of all included studies will 
be reported in tables and summarised in text.
Ethics and dissemination
As the current study is a systematic scoping review 
protocol, ethics is not required. Dissemination of results 
will be made public via peer- reviewed publications, 
conference presentations and lay- person summaries on 
various on- line platforms (eg, The Conversation).
Twitter Rae Thomas @rthomasEBP
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Search Strategies 
PubMed 
(Health[tiab] OR Illness[tiab] OR Disorder[tiab] OR Condition[tiab] OR Disease[tiab]) 
AND 
((Psychological[ti] OR Label[tiab] OR Labelling[tiab] OR Labeling[tiab]) AND 
(Diagnosis[tiab] OR Diagnostic[tiab] OR Screening[Mesh] OR Screening[tiab] OR 
Screened[tiab])) 
AND 
(Patient[tiab] OR Patients[tiab] OR Individuals[tiab] OR Self[tiab] OR Parent[tiab] OR 
Family[tiab] OR Adult[tiab] OR Men[tiab] OR Women[tiab]) 
AND 
(Attitude[Mesh] OR Awareness[tiab] OR Stigma[tiab] OR Beliefs[tiab] OR Well-being[tiab] 
OR Wellbeing[tiab] OR Meaning[tiab] OR Impact[tiab] OR Effect[tiab] OR Effects[tiab] OR 
Influence[tiab] OR Experience[tiab]) 
AND 
(“Systematic review”[tiab] OR "Systematic Review"[pt] OR "Cochrane Database Syst 
Rev"[ta] OR “meta analysis”[pt] OR “meta analysis”[tiab] OR ((Search[tiab] OR 
Searched[tiab] OR Searches[tiab]) AND (PubMed[tiab] OR Medline[tiab] OR Database[tiab] 
OR Databases[tiab])) OR “randomized controlled trial”[pt] OR “controlled clinical trial”[pt] 
OR randomized[tiab] OR randomised[tiab] OR placebo[tiab] OR randomly[tiab] OR 
trial[tiab] OR groups[tiab] OR "Epidemiologic Studies"[Mesh] OR “case-control 
studies”[Mesh] OR “Cohort Studies”[Mesh] OR “case control”[tiab] OR Cohort[tiab] OR 
“Follow up”[tiab] OR Observational[tiab] OR Longitudinal[tiab] OR Prospective[tiab] OR 
retrospective[tiab] OR “cross sectional”[tiab] OR “Cross-Sectional Studies”[Mesh] OR 
Investigated[tiab] OR Analysis[tiab] OR Statistics[tiab] OR Data[tiab] OR "statistics and 
numerical data"[sh] OR "epidemiology"[sh]) 
NOT 
(Animals[Mesh] NOT (Animals[Mesh] AND Humans[Mesh])) 
NOT 
(Injections[Mesh] OR Open-Label[tiab] OR "Product Labeling"[Mesh] OR "Drug 
Labeling"[Mesh] OR "Affinity Labels"[Mesh] OR "Food Labeling"[Mesh] OR "Isotope 
Labeling"[Mesh] OR "Staining and Labeling"[Mesh] OR "In Situ Nick-End Labeling"[Mesh] 
OR "Primed In Situ Labeling"[Mesh] OR Rat[ti] OR Rats[ti] OR Mice[ti] OR Mouse[ti] OR 
Placebo[ti] OR "Drug effects"[sh] OR Drug[ti] OR Drugs[ti] OR "Food and Drug 
Administration"[ti] OR "Food labeling"[ti] OR "Calorie labeling"[ti] OR Injection[ti] OR 
Cigarette[ti])  
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Embase 
(((Health:ti,ab OR Illness:ti,ab OR Disorder:ti,ab OR Condition:ti,ab OR Disease:ti,ab))) 
AND 
((((Psychological:ti OR Label:ti,ab OR Labelling:ti,ab OR Labeling:ti,ab) AND 
(Diagnosis:ti,ab OR Diagnostic:ti,ab OR Screening:ti,ab OR Screening:ti,ab OR 
Screened:ti,ab)))) 
AND 
(((Patient:ti,ab OR Patients:ti,ab OR Individuals:ti,ab OR Self:ti,ab OR Parent:ti,ab OR 
Family:ti,ab OR Adult:ti,ab OR Men:ti,ab OR Women:ti,ab))) 
AND 
(((Attitude:ti,ab OR Awareness:ti,ab OR Stigma:ti,ab OR Beliefs:ti,ab OR Well-being:ti,ab 
OR Wellbeing:ti,ab OR Meaning:ti,ab OR Impact:ti,ab OR Effect:ti,ab OR Effects:ti,ab OR 
Influence:ti,ab OR Experience:ti,ab))) 
AND 
((("Systematic review":ti,ab OR "Systematic Review":it OR "Cochrane Database Syst 
Rev.jn" OR "meta analysis":it OR "meta analysis":ti,ab OR ((Search:ti,ab OR Searched:ti,ab 
OR Searches:ti,ab) AND (PubMed:ti,ab OR Medline:ti,ab OR Database:ti,ab OR 
Databases:ti,ab)) OR "randomized controlled trial":it OR "controlled clinical trial":it OR 
randomized:ti,ab OR randomised:ti,ab OR placebo:ti,ab OR randomly:ti,ab OR trial:ti,ab OR 
groups:ti,ab OR "Epidemiologic Studies" OR "case-control studies" OR "Cohort Studies" OR 
"case control":ti,ab OR Cohort:ti,ab OR "Follow up":ti,ab OR Observational:ti,ab OR 
Longitudinal:ti,ab OR Prospective:ti,ab OR retrospective:ti,ab OR "cross sectional":ti,ab OR 
"Cross-Sectional Studies" OR Investigated:ti,ab OR Analysis:ti,ab OR Statistics:ti,ab OR 
Data:ti,ab OR epidemiology:ti,ab))) 
NOT 
(((Injections OR Open-Label:ti,ab OR "Product Labeling" OR "Drug Labeling" OR "Drug 
Therapy" OR "Affinity Labels" OR "Food Labeling" OR "Isotope Labeling" OR "Staining 
and Labeling" OR "In Situ Nick-End Labeling" OR "Primed In Situ Labeling" OR Rat:ti OR 
Rats:ti OR Mice:ti OR Mouse:ti OR Placebo:ti OR "Drug effects.hw" OR Drug:ti OR 
Drugs:ti OR "Off Label":ti,ab OR Food AND "Drug Administration":ti OR "Food 
labeling":ti OR "Calorie labeling":ti OR Injection:ti OR Cigarette:ti)))  
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PsychINFO 
((Health.ti,ab OR Illness.ti,ab OR Disorder.ti,ab OR Condition.ti,ab OR Disease.ti,ab)) 
AND 
(((Psychological.ti OR Label.ti,ab OR Labelling.ti,ab OR Labeling.ti,ab) AND 
(Diagnosis.ti,ab OR Diagnostic.ti,ab OR Screening.ti,ab OR Screening.ti,ab OR 
Screened.ti,ab))) 
AND 
((Patient.ti,ab OR Patients.ti,ab OR Individuals.ti,ab OR Self.ti,ab OR Parent.ti,ab OR 
Family.ti,ab OR Adult.ti,ab OR Men.ti,ab OR Women.ti,ab)) 
AND 
((Attitude.ti,ab OR Awareness.ti,ab OR Stigma.ti,ab OR Beliefs.ti,ab OR Well-being.ti,ab 
OR Wellbeing.ti,ab OR Meaning.ti,ab OR Impact.ti,ab OR Effect.ti,ab OR Effects.ti,ab OR 
Influence.ti,ab OR Experience.ti,ab)) 
AND 
((Systematic review.ti,ab OR Systematic Review.pt OR Cochrane Database Syst Rev.jn OR 
meta analysis.pt OR meta analysis.ti,ab OR ((Search.ti,ab OR Searched.ti,ab OR 
Searches.ti,ab) AND (PubMed.ti,ab OR Medline.ti,ab OR Database.ti,ab OR 
Databases.ti,ab)) OR randomized controlled trial.pt OR controlled clinical trial.pt OR 
randomized.ti,ab OR randomised.ti,ab OR placebo.ti,ab OR randomly.ti,ab OR trial.ti,ab OR 
groups.ti,ab OR "Epidemiologic Studies" OR "case-control studies" OR "Cohort Studies" OR 
case control.ti,ab OR Cohort.ti,ab OR Follow up.ti,ab OR Observational.ti,ab OR 
Longitudinal.ti,ab OR Prospective.ti,ab OR retrospective.ti,ab OR cross sectional.ti,ab OR 
"Cross-Sectional Studies" OR Investigated.ti,ab OR Analysis.ti,ab OR Statistics.ti,ab OR 
Data.ti,ab OR epidemiology.ti,ab)) 
NOT 
((Injections OR Open-Label.ti,ab OR "Product Labeling" OR "Drug Labeling" OR "Drug 
Therapy" OR "Affinity Labels" OR "Food Labeling" OR "Isotope Labeling" OR "Staining 
and Labeling" OR "In Situ Nick-End Labeling" OR "Primed In Situ Labeling" OR Rat.ti OR 
Rats.ti OR Mice.ti OR Mouse.ti OR Placebo.ti OR Drug effects.hw OR Drug.ti OR Drugs.ti 
OR Off Label.ti,ab OR Food and Drug Administration.ti OR Food labeling.ti OR Calorie 
labeling.ti OR Injection.ti OR Cigarette.ti)) 
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Cochrane 
(((Health:ti,ab OR Illness:ti,ab OR Disorder:ti,ab OR Condition:ti,ab OR Disease:ti,ab))) 
AND 
((((Psychological:ti OR Label:ti,ab OR Labelling:ti,ab OR Labeling:ti,ab) AND 
(Diagnosis:ti,ab OR Diagnostic:ti,ab OR Screening:ti,ab OR Screening:ti,ab OR 
Screened:ti,ab)))) 
AND 
(((Patient:ti,ab OR Patients:ti,ab OR Individuals:ti,ab OR Self:ti,ab OR Parent:ti,ab OR 
Family:ti,ab OR Adult:ti,ab OR Men:ti,ab OR Women:ti,ab))) 
AND 
(((Attitude:ti,ab OR Awareness:ti,ab OR Stigma:ti,ab OR Beliefs:ti,ab OR Well-being:ti,ab 
OR Wellbeing:ti,ab OR Meaning:ti,ab OR Impact:ti,ab OR Effect:ti,ab OR Effects:ti,ab OR 
Influence:ti,ab OR Experience:ti,ab))) 
AND 
((("Systematic review":ti,ab OR "Systematic Review":pt OR "Cochrane Database Syst 
Rev.jn" OR "meta analysis":pt OR "meta analysis":ti,ab OR ((Search:ti,ab OR Searched:ti,ab 
OR Searches:ti,ab) AND (PubMed:ti,ab OR Medline:ti,ab OR Database:ti,ab OR 
Databases:ti,ab)) OR "randomized controlled trial":pt OR "controlled clinical trial":pt OR 
randomized:ti,ab OR randomised:ti,ab OR placebo:ti,ab OR randomly:ti,ab OR trial:ti,ab OR 
groups:ti,ab OR "Epidemiologic Studies" OR "case-control studies" OR "Cohort Studies" OR 
"case control":ti,ab OR Cohort:ti,ab OR "Follow up":ti,ab OR Observational:ti,ab OR 
Longitudinal:ti,ab OR Prospective:ti,ab OR retrospective:ti,ab OR "cross sectional":ti,ab OR 
"Cross-Sectional Studies" OR Investigated:ti,ab OR Analysis:ti,ab OR Statistics:ti,ab OR 
Data:ti,ab OR epidemiology:ti,ab))) 
NOT 
(((Injections OR Open-Label:ti,ab OR "Product Labeling" OR "Drug Labeling" OR "Drug 
Therapy" OR "Affinity Labels" OR "Food Labeling" OR "Isotope Labeling" OR "Staining 
and Labeling" OR "In Situ Nick-End Labeling" OR "Primed In Situ Labeling" OR Rat:ti OR 
Rats:ti OR Mice:ti OR Mouse:ti OR Placebo:ti OR "Drug effects.hw" OR Drug:ti OR 
Drugs:ti OR "Off Label":ti,ab OR Food AND "Drug Administration":ti OR "Food 
labeling":ti OR "Calorie labeling":ti OR Injection:ti OR Cigarette:ti))) 
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CINAHL 
(((TI Health OR AB Health OR TI Illness OR AB Illness OR TI Disorder OR AB Disorder 
OR TI Condition OR AB Condition OR TI Disease OR AB Disease))) 
AND 
((((TI Psychological OR TI Label OR AB Label OR TI Labelling OR AB Labelling OR TI 
Labeling OR AB Labeling) AND (TI Diagnosis OR AB Diagnosis OR TI Diagnostic OR AB 
Diagnostic OR TI Screening OR AB Screening OR TI Screening OR AB Screening OR TI 
Screened OR AB Screened)))) 
AND 
(((TI Patient OR AB Patient OR TI Patients OR AB Patients OR TI Individuals OR AB 
Individuals OR TI Self OR AB Self OR TI Parent OR AB Parent OR TI Family OR AB 
Family OR TI Adult OR AB Adult OR TI Men OR AB Men OR TI Women OR AB 
Women))) 
AND 
(((TI Attitude OR AB Attitude OR TI Awareness OR AB Awareness OR TI Stigma OR AB 
Stigma OR TI Beliefs OR AB Beliefs OR TI Well-being OR AB Well-being OR TI 
Wellbeing OR AB Wellbeing OR TI Meaning OR AB Meaning OR TI Impact OR AB 
Impact OR TI Effect OR AB Effect OR TI Effects OR AB Effects OR TI Influence OR AB 
Influence OR TI Experience OR AB Experience))) 
AND 
(((TI "Systematic review" OR AB "Systematic review" OR PT "Systematic Review" OR 
"Cochrane Database Syst Rev.jn" OR PT "meta analysis" OR TI "meta analysis" OR AB 
"meta analysis" OR ((TI Search OR AB Search OR TI Searched OR AB Searched OR TI 
Searches OR AB Searches) AND (TI PubMed OR AB PubMed OR TI Medline OR AB 
Medline OR TI Database OR AB Database OR TI Databases OR AB Databases)) OR PT 
"randomized controlled trial" OR PT "controlled clinical trial" OR TI randomized OR AB 
randomized OR TI randomised OR AB randomised OR TI placebo OR AB placebo OR TI 
randomly OR AB randomly OR TI trial OR AB trial OR TI groups OR AB groups OR 
"Epidemiologic Studies" OR "case-control studies" OR "Cohort Studies" OR TI "case 
control" OR AB "case control" OR TI Cohort OR AB Cohort OR TI "Follow up" OR AB 
"Follow up" OR TI Observational OR AB Observational OR TI Longitudinal OR AB 
Longitudinal OR TI Prospective OR AB Prospective OR TI retrospective OR AB 
retrospective OR TI "cross sectional" OR AB "cross sectional" OR "Cross-Sectional Studies" 
OR TI Investigated OR AB Investigated OR TI Analysis OR AB Analysis OR TI Statistics 
OR AB Statistics OR TI Data OR AB Data OR TI epidemiology OR AB epidemiology))) 
NOT 
(((Injections OR TI Open-Label OR AB Open-Label OR "Product Labeling" OR "Drug 
Labeling" OR "Drug Therapy" OR "Affinity Labels" OR "Food Labeling" OR "Isotope 
Labeling" OR "Staining and Labeling" OR "In Situ Nick-End Labeling" OR "Primed In Situ 
Labeling" OR TI Rat OR TI Rats OR TI Mice OR TI Mouse OR TI Placebo OR "Drug 
effects.hw" OR TI Drug OR TI Drugs OR TI "Off Label" OR AB "Off Label" OR Food 
AND TI "Drug Administration" OR TI "Food labeling" OR TI "Calorie labeling" OR TI 
Injection OR TI Cigarette))) 
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